NOTICE

ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

I hereby authorize the temporary use of the following alternative medication:

| 99114119 Heparin sodium | 1 ml 5000 U/0.5 mL | . Inj. Sol. | | |
|-------------------------|--------------------|-------------|--|--|
|-------------------------|--------------------|-------------|--|--|

until the following medication appearing on the List of Medications attached to the Regulation respecting the list of Medications covered by the basic prescription drug insurance plan is no longer out of stock:

| 02382326 | Heparin sodium injection, USP | Pfizer | 1 ml | 10,000 U/mL | Inj. Sol. | 5.01 | 5.0100 | |
|----------|-------------------------------|--------|------|-------------|-----------|------|--------|--|
|----------|-------------------------------|--------|------|-------------|-----------|------|--------|--|

This notice has effect retroactively from 6 December 2022 and replaces the notice of replacement of 16 December 2022 for Heparin sodium injection, USP with effect from 6 December 2022.

Québec, 12 January 2023

[original signed by]

MARCO THIBAULT President and Chief Executive Officer Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.